An observational study in Acute Myeloid Leukemia, sponsored by University of Freiburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by University of Freiburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 281 studies in Leukemia, Myeloid, Acute with a site in Germany — 32 open to participants now, 54 under way, 18 of them phase 3. Leukemia, Myeloid, Acute · Germany.
Among the 281 studies in Leukemia, Myeloid, Acute with a site in Germany, this one is the 16th largest by planned enrollment of the 18 observational ones that give a count, is one of 6 that started in 2026, is one of 18 observational ones, reaches primary completion later than 21 of the 53 other live ones, and was the 281st registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →32 of the 281 studies in Leukemia, Myeloid, Acute with a site in Germany are open now. Recruiting first, the newest first:
Stichting Hemato-Oncologie voor Volwassenen Nederland · Sites in Germany, United States, Australia and 10 more countries
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 18–75 · Healthy volunteers
Technische Universität Dresden · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 6 more countries
Ages 16+
Syndax Pharmaceuticals · Sites in Germany, United States, Argentina and 20 more countries
Ages 12+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
281 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 127 · Phase 3 88 · Phase 4 5
First in 1993; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 126 across the 261 interventional studies, 135 across the 18 observational. Of the 204 that completed or were terminated, 76 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 281 have an industry lead sponsor. The 10 most frequent:
University of Freiburg is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
University of Freiburg has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
15 of the studies in Leukemia, Myeloid, Acute with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT03839771Phase 3Stichting Hemato-Oncologie voor Volwassenen NederlandA Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | 2027-04-17 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03897127Phase 3University of UlmStudy of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | 2027-06 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 281 studies in Leukemia, Myeloid, Acute with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
The study will investigate biomarkers including humen endogenous retrovirus expression and T cell phenotypic analysis in patients with AML with NPM1 mutations or KMT2A rearrangements. These biomarkers have been previously described: Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712. PMID: 41144759
Patients with AML with NPM1 mutations or KMT2A rearrangements that experience a hematological relapse after allo-HCT
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AML with NPM1 mutations or KMT2A rearrangements that will be treated with immunotherapy (DLI) and immunmodulatory drugs recommended by the guidelines.
Correlative biomarker
HERV expression by AML cells
Time frame: 1 year
Biomarkers will be correlated with survival and leukemia response
The biomarkers HERV, HLA class I and II, T cell phenotype
Time frame: may 2026 till may 2027
Plan to share: No
Start is estimated for May 2026; primary completion for May 2027, 12 months later.
Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 12 months is below that.
Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Freiburg